MedTrace Logo

A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

NCT00190489 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2016-09-02

No results posted yet for this study

Summary

To investigate the clinical benefits of Docetaxel or alternating AC-Docetaxel in comparison with standard AC for metastatic breast cancer

Conditions

Interventions

DRUG

AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles

DRUG

Docetaxel 60mg/m2 every 21 days for 6 cycles

DRUG

AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles

Sponsors & Collaborators

  • Ministry of Health, Labour and Welfare, Japan

    collaborator OTHER_GOV

  • Japan Clinical Oncology Group

    lead OTHER

Principal Investigators

  • Shigemitsu Takashima, MD, PhD · National Shikoku Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-01-31
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00190489 on ClinicalTrials.gov